期刊文献+

经肾动脉栓塞术对常染色体显性多囊肾病终末期的对症治疗 被引量:1

Renal arterial embolization for symptomatic management of end-stage autosomal dominant polycystic kidney disease
下载PDF
导出
摘要 目的评价经肾动脉栓塞术在常染色体显性多囊肾病对症治疗中的安全性和疗效。方法2007年12月至2013年3月收治终末期多囊肾病患者7例,因内科保守治疗无效而行肾动脉栓塞术治疗。7例患者均表现为严重腹胀,5例伴肉眼血尿,1例伴顽固性高血压。结果术后随访10~36个月,7例患者临床症状均有不同程度缓解,同时腹围变小,营养状况改善。无严重并发症发生。结论经肾动脉栓塞术对终末期多囊肾的对症治疗是安全有效的。 Objective To evaluate the efficacy and safety of transarterial embolization for symptomatic management of end-stage autosomal dominant polycystic kidney disease. Methods During the period from December 2007 to March 2013, seven patients with end-stage autosomal dominant polycystic kidney disease were admitted to the hospital. As the patients failed to respond to medical conservative measures transarterial embolization therapy using PVA particles, Gelfoam or coils was carried out in all of them. Clinically, the primary manifestation of the disease was severe abdominal distension in all patients. Gross hematuria was seen in 5 cases and refractory hypertension in one case. Results Unilateral renal arterial embolization was successfully performed in 6 patients, while bilateral renal arterial embolization was accomplished in one patient. All patients were followed up for 10 - 36 months. Different degrees of improvement in clinical symptoms were obtained in all the patients. The abdominal perimeter decreased, and the patient's nutritional status was improved. No severe complications occurred. Conclusion For the symptomatic management of end-stage dominant polycystic kidney disease, renal arterial embolization is safe and effective. (J Intervent Radiol, 2013, 22: 461-463)
出处 《介入放射学杂志》 CSCD 北大核心 2013年第6期461-463,共3页 Journal of Interventional Radiology
关键词 常染色体显性多囊肾病 动脉栓塞 对症治疗 autosomal dominant polycystic kidney disease transarterial embolization symptomaticmanagement
  • 相关文献

参考文献12

  • 1Maxwell NJ,Saleem AN,Rogers E,et al.Renal artery embolisation in the palliative treatment of renal carcinoma[J].Br J Radiol,2007,80:96-102. 被引量:1
  • 2Cho KJ,Stanley JC.Non-neoplastic congenital and acquired renal arteriovenous malformations and fistulas[J].Radiology,1978,129:333-343. 被引量:1
  • 3Bennett WM,Elzinga L,Golper TA,et al.Reduction of cyst volume for symptomatic management of autosomal dominant polycystic kidney disease[J].J Urol,1987,137:620-622. 被引量:1
  • 4Uemasu J,FuJiwara M,Munemura C,et al.Effects of topical instillation of minocycline hydrochloride on cyst size and renal function in polycystic kidney disease[J].Clin Nephrol,1993,39:140-144. 被引量:1
  • 5Elzinga LW,Barry JM,Torres VE,et al.Cyst decompression surgery for autosomal dominant polycystic kidney disease[J].J Am Soc Nephrol,1992,2:1219-1226. 被引量:1
  • 6Elashry OM,Nakada SY,Wolf JS,et al.Laparoscopy for adult polycystic kidney disease:a promising alternative[J].Am J Kidney Dis,1996,27:224-233. 被引量:1
  • 7戴兵,刘亚伟,梅长林.多囊肾病实验及治疗进展[J].中华肾脏病杂志,2006,22(11):713-716. 被引量:4
  • 8Harley JD,Shen FH,Carter SJ.Transcatheter infarction of a polycystic kidney for control of recurrent hemorrhage[J].Am J Roentgenol,1980,134:818-820. 被引量:1
  • 9Ubara Y.New therapeutic option for autosomal dominant polycystic kidney disease patients with enlarged kidney and liver[J].Ther Apher Dial,2006,10:333-341. 被引量:1
  • 10Takei R,Ubara Y,Hoshino J,et al.Percutaneous transcatheter hepatic artery embolization for liver cysts in autosomal dominant polycystic kidney disease[J].Am J Kidney Dis,2007,49:744-752. 被引量:1

二级参考文献30

  • 1Torres VE.Therapies to slow polycystic kidney disease.Nephron Exp Nephrol,2004,98:e1-e7. 被引量:1
  • 2Davis ID,MacRae Dell K,Sweeney WE,et al.Can progression of autosomal dominant or autosomal recessive polycystic kidney disease be prevented? Semin Nephrol,2001,21:430-440. 被引量:1
  • 3Wilson PD.Polycystic kidney disease.N Engl J Med,2004,350:151-164. 被引量:1
  • 4Sweeney WE Jr,Hamahira K,Sweeney J,et al.Combination treatment of PKD utilizing dual inhibition of EGF-receptor activity and ligand bioavailability.Kidney Int,2003,64:1310-1319. 被引量:1
  • 5Tao Y,Kim J,Schrier RW,et al.Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease.J Am Soc Nephrol,2005,16:46-51. 被引量:1
  • 6Shillingford JM,Murcia NS,Larson CH,et al.The mTOR pathway is regulated by polycystin-l,and its inhibition reverses renal cystogenesis in polycystic kidney disease.Proc Natl Acad Sci U S A,2006,103:5466-5471. 被引量:1
  • 7Mostov KE.mTOR is out of control in polycystic kidney disease.Proc Natl Acad Sci U S A,2006,103:5247-5248. 被引量:1
  • 8Tao Y,Kim J,Faubel S,Wu JC,et al.Caspase inhibition reduces tubular apoptosis and proliferation and slows disease progression in polycystic kidney disease.Proc Natl Acad Sci USA,2005,102:6954-6959. 被引量:1
  • 9Torres VE.Cyclic AMP,at the hub of the cystic cycle.Kidney Int,2004,66:1283-1285. 被引量:1
  • 10Gattone VH 2nd,Wang X,Harris PC,et al.Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist.Nat Med,2003,9:1323-1326. 被引量:1

共引文献6

同被引文献3

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部